Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
10/2008
10/30/2008WO2008008383A3 System and methods for measuring a skin protection factor
10/30/2008WO2007140416A3 Two-piece, internal-channel osmotic delivery system flow modulator
10/30/2008WO2007126136A3 Mask- tasting solid preparation of pioglitazone
10/30/2008WO2007112356A3 Core-shell nanocapsules and applications thereof
10/30/2008WO2007109180A3 Stabilized, sterilized collagen scaffolds with active adjuncts attached
10/30/2008WO2006073950A3 Nanoparticles for protein drug delivery
10/30/2008WO2004112717A3 Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
10/30/2008US20080269875 Coating for a Medical Device Having an Anti-Thrombotic Conjugate
10/30/2008US20080269726 Osmotic pump with self-retaining, fast-start membrane plug
10/30/2008US20080269725 Osmotically Driven Dispense Pump and Related Components for Use in High Pressure Applications
10/30/2008US20080269551 Steerable lesion excluding heart implants for congestive heart failure
10/30/2008US20080269331 Omega -3 series polyunsaturated fatty acids are selected from eicosapentanoic acid, docosahexaenoic acid, eicosapentanoic acid, ethyl ester, docosahexaenoic acid, ethyl ester; infarct of the myocardium; coronary ischemia; atrial fibrillation
10/30/2008US20080269308 Allantoin-containing skin cream
10/30/2008US20080269198 Oral administering; drug with carrier and excipient
10/30/2008US20080269181 Methods for treating a posterior segment of an eye
10/30/2008US20080269178 Antiinflammatory agents; heating glucocorticoid with water and surfactant
10/30/2008US20080269166 O-desmethylvenlafaxine succinate; tablet, capsule; sustained release; hydroxypropylmethyl cellulose rate controlling polymer; microcrystalline cellulose binder; depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease
10/30/2008US20080269147 Used in targeting specific mRNAs for degradation in mammalian cells where use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response; autoimmune disease; tumor-associated gene
10/30/2008US20080269134 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
10/30/2008US20080268063 Coated Controlled Release Polymer Particles as Efficient Oral Delivery Vehicles for Biopharmaceuticals
10/30/2008US20080268062 Stabilized particle dispersions containing surface-modified inorganic nanoparticles
10/30/2008US20080268061 injection solutions containing the nanoparticles as well as to the use thereof for the treatment of cancer; release of the therapeutically active substances is caused, initiated or substantially enhanced by an alternating magnetic field
10/30/2008US20080268060 passing a liquid nanoscale particle precursor material through a flow passage heated to convert the carrier into a vapor and the second component into nanoscale particles; can be incorporated in a hand held inhaler, and can be delivered to a targeted portion of the lung using the inhaler
10/30/2008US20080268059 Immobilizing particles onto surfaces
10/30/2008US20080268058 Particles
10/30/2008US20080268057 Controlled release carvedilol compositions
10/30/2008US20080268056 Injectable copolymer hydrogel useful for repairing vertebral compression fractures
10/30/2008US20080268055 administering a micro-emulsion comprising at least one surfactant having a HLB value between 5 and 15, at least one lipophilic substance, and water
10/30/2008US20080268054 Dermal derived human stem cells and compositions and methods thereof
10/30/2008US20080268053 Collagen carrier of therapeutic genetic material, and method
10/30/2008US20080268052 exhibits an enhanced rate of polymerization and enhanced microstructural and mechanical properties upon polymerization
10/30/2008US20080268051 Anti-angiogenesis; viscosity inducing component is injectable into the vitreous of a mammalian eye without permanently diminishing visual acuity
10/30/2008US20080268050 Sprayable topical skin barriers
10/30/2008US20080268049 having reduced levels of 3-ethyl methyl [(2-aminoethoxy)methyl](2-chlorophenyl)methylpyridine-3,5 dicarboxylate ("impurity D") and total impurities when free of dicalcium phosphate
10/30/2008US20080268048 Pharmaceutical composition for contraception and for reducing the risk of congenital abnormalities
10/30/2008US20080268047 supplying a plurality of solutions with syringe pumps for fluid bed coating, coating a substrate with a pH dependent soluble polymer solution, coating the polymer coated substrate with layer of a solution of a therapeutically active substance and layer of a second polymer solution and alternating
10/30/2008US20080268046 For phosphodiesterase inhibitor vardenafil
10/30/2008US20080268045 Sustained release methotrexate formulations and methods of use thereof
10/30/2008US20080268044 Novel Process and Formulations
10/30/2008US20080268043 Controlled Release Compositions Comprising an Antipsychotic Agent
10/30/2008US20080268042 Omega 3 fatty acid formulations
10/30/2008US20080268041 Composition of 11 beta -(4-acetylphenyl)-17 beta -hydroxy-17 alpha -(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one and Tamoxifen; inhibits growth of breast cells
10/30/2008US20080268040 Organic Compounds Comprising a Glycopyrrolium Salt
10/30/2008US20080268039 Loquat compositions
10/30/2008US20080268038 Composition of essential amino acids L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-valine and L-threonine
10/30/2008US20080268037 Swallowing a mobile self-controlled capsule with sensors, internal chip containing a healing substance; sending control signals from sensors to the chip; high precision targeting of damaged regions; avoiding exposure of non-damaged regions to healing substances
10/30/2008US20080268036 Co-processing of active pharmaceutical/nutraceutical ingredients
10/30/2008US20080268035 Cationic Polymer Nanoparticles Encapsulating An Active Ingredients, And The Cosmetic Composition Containing The Same
10/30/2008US20080268034 High surface area of colloidal silicon dioxide neutralizes the surface charges from the particles which then de-segregate into individual particles, with colloidal silicon dioxide acting as a drug carrier; easily processed into a desired dosage form
10/30/2008US20080268033 Biologically active methylene blue derivatives
10/30/2008US20080268032 Stabilizing Alkylglycoside Compositions and Methods Thereof
10/30/2008US20080268031 Therapeutic Treatment of Dermatologic Skin Disorders
10/30/2008US20080268030 Gene therapy for diabetic ischemic disease
10/30/2008US20080268029 Peptide fragment with immunogenic or therapeutic properties against ischemic cardiovascular diseases
10/30/2008US20080268028 Lyophilization of virosomes
10/30/2008US20080268027 Oral administering a drug; drying self-supporting polymer film and drug dosage
10/30/2008US20080268025 Compositions Useful for Preventing Pain and Soreness Resulting from Exercise and Methods of Use
10/30/2008US20080268023 Sufentanil and a bioadhesive material, for sublingual administration
10/30/2008US20080268022 Mehtods for treating and preventing ailments caused by human papillomavirus
10/30/2008US20080268021 Adhesive bioerodible ocular drug delivery system
10/30/2008US20080268020 Ophthalmic Emulsions Containing Prostaglandins
10/30/2008US20080268014 Ethanamine, 2-L[5-oxido-4-phenylsulfonyl)-1,2,5-oxadiazol-3-yl]oxy]-N,N-bis[2-[[5-oxido-4-(phenylsulfonyl)-1,2,5-oxadiazol-3-yl]oxy]ethyl]-; cardiovascular diseases; inhibiting platelet aggregation, platelet adhesion caused by the exposure of blood to a medical device; abnormal cell proliferation
10/30/2008US20080268008 Methods to Control Termites
10/30/2008US20080268006 Probiotic Lactobacillus Strains for Improved Vaginal Health
10/30/2008US20080268004 Stable Water-In-Oil-In-Water Multiple Emulsion System Produced By Hydrodynamic Dual Stabilization And A Method For Preparation Thereof
10/30/2008US20080267963 Administering individual an antigen-liposome preparation to treat and prevent cell proliferative disorders
10/30/2008US20080267919 Solid support for initiating neovascularization; blood vessels fomation; targeted neovascularization; tissue target therapy
10/30/2008US20080267888 Heterocyclic Derivatives
10/30/2008US20080267887 Such as 5-(2,6-diethyl-phenyl)-1H-pyrrolo[2,3-C]pyridine, which binds C5a receptors with high affinity; for treatment of inflammatory, cardiovascular, and immune system disorders; kits
10/30/2008US20080267886 Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists
10/30/2008US20080267885 Medicinal Compositions and Method for the Preparation Thereof
10/30/2008US20080267877 Administering carrier molecule such as albumin conjugated to mannose-6-phosphate; particularly targeting Hepatic Stellate Cells (HSC); glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, Crohn's disease, colitis ulcerosa, glomerulonephritis and sepsis; diagnosis
10/30/2008US20080267876 Nanoparticles for Targeted Delivery of Active Agent
10/30/2008US20080264416 Method of Treating Diabetes Mellitus in a Patient
10/30/2008CA2720269A1 Composition for enhancing bone formation
10/30/2008CA2690772A1 Novel peptide amphiphiles having improved solubility and methods of using same
10/30/2008CA2686093A1 Solvent-cast microneedle arrays containing active
10/30/2008CA2684752A1 Ultrasound imaging with targeted microbubbles
10/30/2008CA2684718A1 A foam material for medical use and method for producing same
10/30/2008CA2684586A1 High dose composition of ursodeoxycholic acid
10/30/2008CA2684550A1 Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
10/30/2008CA2684170A1 Process for dosing self-emulsifying drug delivery systems
10/30/2008CA2683974A1 Protein-modified nano-droplets, compositions and methods of production
10/30/2008CA2683940A1 Nanoparticle-coated capsule formulation for dermal drug delivery
10/30/2008CA2683698A1 A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
10/30/2008CA2683672A1 Ophthalmic oil-in-water emulsions containing prostaglandins
10/30/2008CA2682551A1 Embedded liquid lubricants for tableting
10/30/2008CA2682300A1 Process for producing preparation for oral administration
10/30/2008CA2682135A1 Nucleic acid microparticles for pulmonary delivery
10/30/2008CA2682127A1 Pulmonary delivery of spherical insulin microparticles
10/30/2008CA2681587A1 Stabilised pharmaceutical composition containing pregabaline
10/30/2008CA2681181A1 Sustained release
10/30/2008CA2680039A1 Pharmaceutical composition comprising edoxaban, an anticoagulant
10/30/2008CA2659603A1 Oil producing microbes and methods of modification thereof
10/29/2008EP1985699A1 Controlled dissolution crosslinked protein crystals
10/29/2008EP1985310A1 Solid dosage forms
10/29/2008EP1985309A1 Nanoparticle containing water-soluble non-peptidic low molecular weight substance
10/29/2008EP1985308A2 Water-soluble compositions of bioactive lipophilic compounds
10/29/2008EP1985303A1 Oral composition containing interferon-
10/29/2008EP1985298A1 Ophtalmic oil-in-water emulsions containing prostaglandins
1 ... 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 ... 2991